Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 10/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 10/20 | 0.78 |
| ▸ | PDE2A | O00408 | 10/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | TSPO | P30536 | 1/20 | 0.66 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | PTGFR | P43088 | 1/20 | 0.66 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904869 | 0.91 | MEN1 (0.82) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL6901464 | 0.90 | TBXA2R (0.89) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL6902249 | 0.89 | MEN1 (0.80) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL9518470 | 0.88 | TBXA2R (1.00) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL6901522 | 0.87 | PTGDR (0.81) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL6948603 | 0.87 | TBXA2R (0.77) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL6907420 | 0.86 | TBXA2R (0.80) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL6903085 | 0.86 | TBXA2R (0.80) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL10471370 | 0.86 | TBXA2R (0.78) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL6949873 | 0.85 | PDE2A (0.85) | MEN1ALDH1A1CYP3A4MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242068-A4 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED INC (US) | 2007-04-25 | — | — | EP | claimed |
| US-20030109543-A1 | Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination | OGLETREE MARTIN L (US) | 2003-06-12 | — | — | US | claimed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | claimed |
| EP-1242068-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | Nitromed, Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001089519-A1 | THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS | NITROMED, INC. (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001032167-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED, INC. (US) | 2001-05-10 | — | — | WO | claimed |
| US-5462726-A | Suppressing vasoconstriction | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-31 | — | — | US | claimed |
| EP-0448274-A2 | Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of ulcerative gastrointestinal conditions | E.R. SQUIBB & SONS, INC. (US) | 1991-09-25 | — | — | EP | claimed |
| EP-0310179-A2 | Tetrahydrocarbazole esters | MERCK FROSST CANADA INC. (CA) | 1989-04-05 | — | — | EP | claimed |
| EP-0307077-A1 | Tetrahydrocarbazoles for the improvement of cyclosporin therapy | MERCK FROSST CANADA INC. (CA) | 1989-03-15 | — | — | EP | claimed |
| EP-0300676-A2 | Tetrahydrocarbazole 1-alkanoic acids | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | claimed |
| US-20230129262-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19 | OGLETREE MARTIN (US) | 2023-04-27 | — | — | US | disclosed |
| CN-115666560-A | Methods and pharmaceutical compositions for treating thromboxane A2 receptor antagonists of COVID-19 | 马丁·奥格特树 | 2023-01-31 | — | — | CN | disclosed |
| CN-115624549-A | Compositions and methods for treating muscular dystrophy using thromboxane-A2 receptor antagonists | 坎伯兰医药品股份有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-109152767-B | Compositions and methods for treating muscular dystrophy using thromboxane-A2 receptor antagonists | 坎伯兰医药品股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-0310179-A2 | Tetrahydrocarbazole esters | MERCK FROSST CANADA INC. (CA) | 1989-04-05 | — | — | EP | disclosed |
| EP-0307077-A1 | Tetrahydrocarbazoles for the improvement of cyclosporin therapy | MERCK FROSST CANADA INC. (CA) | 1989-03-15 | — | — | EP | disclosed |
| US-4808608-A | ANTIALLERGENS, HYPOTENSIVE AGENT, ANTICOAGULANT | MERCK & CO., INC. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0300675-A2 | Method for the improvement of cyclosporine therapy | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | disclosed |
| EP-0300676-A2 | Tetrahydrocarbazole 1-alkanoic acids | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109543-A1 | Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination | PTAFR, TBXA2R, PLAT | MEN1 3049/4885ALDH1A1 1871/4885CYP3A4 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.